Sulindac sodium

Synonyms: 舒林酸(钠); MK-231 sodium
Sulindac (MK-231) 是一种口服活性非甾体类抗炎药,也是一种免疫调节剂,可用于脊柱关节炎、痛风性关节炎及结直肠癌、肺癌等多种癌症的研究。
产品编号: MS-S42663 CAS No.: 63804-15-9 分子式: C20H16FNaO3S 分子量: 378.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Sulindac (MK-231) 是一种口服活性非甾体类抗炎药,也是一种免疫调节剂,可用于脊柱关节炎、痛风性关节炎及结直肠癌、肺癌等多种癌症的研究。

生物实验数据

生物活性 Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory drug and an immunomodulator, and can be used in research on spondyloarthritis, gouty arthritis, and various cancers such as colorectal cancer and lung cancer.
体外研究
(In Vitro)

Sulindac (MK-231) (500 μM, 48 h) sodium is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors.
Sulindac sodium (500 μM, 48 h) can inhibit TGF-β1-enhanced migration and invasion of A549 cells.
Sulindac sodium (500 μM, 48 h) enhances the reversal of TGF-β1-induced EMT by sulindac (sodium) and SIRT1 upregulation promoted TGF-β1-induced EMT.

Western Blot Analysis

Cell Line: A549 cells
Concentration: 500 μM
Incubation Time: 48 h
Result: Inhibit transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in A549 cells.

Immunofluorescence

Cell Line: A549 cells
Concentration: 500 μM
Incubation Time: 48 h
Result: Reversed SIRT-1 expression by TGF-β1 and inhibited the TGF-β1-induced cadherin switch.

Cell Migration Assay

Cell Line: A549 cells
Concentration: 500 μM
Incubation Time: 48 h
Result: Inhibited migration, decreased resistance co-treatment with TGF-β1.

Cell Invasion Assay

Cell Line: A549 cells
Concentration: 500 μM
Incubation Time: 40 h; 48 h
Result: Could effectively inhibit the TGF- β1-induced increase in invasion by lung cancer cells.
体内研究
(In Vivo)

Sulindac (MK-231) sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) shows a significant reduction in tumor volume and increases infiltration of CD8+ T lymphocytes in the tumor tissues when treated with combination therapy.
Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P.
Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy.
Sulindac sodium has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose does.

Animal Model: CT26 syngeneic mouse tumor model
Dosage: 15 mg/kg; 7.5 mg/kg
Administration: 15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
Result: Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy.
Animal Model: CT26 syngeneic mouse tumor model
Dosage: 15 mg/kg; 7.5 mg/kg
Administration: 15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
Result: Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy.
Cound effectively inhibit PD-L1 with no significant systematic toxicity.

化学信息

分子量 378.39
分子式 C20H16FNaO3S
CAS No. 63804-15-9
别名 舒林酸(钠); MK-231 sodium

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础